Skip to main content

Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

Active, not recruiting · Not applicable · NCT06096337

Conditions: Persistent Atrial Fibrillation

At a glance

Research payments reported, 2025
$2.1M
U.S. investigators named
46
Sites paid
47
Planned or actual enrollment
484

About the trial

Sponsor
Boston Scientific Corporation
Tested
FARAPULSE™ Pulsed Field Ablation (PFA) System (device), Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone (drug)
Dates
Started 2023-12-28; completion 2028-02-04
Results posted
Not yet

The purpose of this study is to establish the safety and effectiveness of pulsed field ablation as a first-line ablation treatment for subjects with persistent atrial fibrillation as compared to subjects who received an initial treatment with anti-arrhythmic drugs.

From ClinicalTrials.gov, last updated 2026-08-28. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $2.1M in research payments for this study in 2025 (267 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.